Table 4.

Subgroup analyses of the prognostic role of GPS for OS.

Subgroup	No. of studies	No. of participants	HR	95% CI	p value	I 2
Histology type
Bone sarcoma	4	672	2.35	1.84-3.01	p < 0.001	1.0%
Soft tissue sarcoma	3	474	2.53	1.83-3.52	p < 0.001	15.01%
Analysis method
Multivariate analysis	3	449	2.78	1.90-4.05	p < 0.001	5.2%
Univariate analysis	4	647	2.29	1.82-2.89	p < 0.001	0.0%
Ethnicity
Asian	6	984	2.27	1.83-2.81	p < 0.001	0.0%
Other	1	162	3.39	2.06-5.56	p < 0.001	—
Inflammation diseases
Excluded	5	881	2.31	1.82-2.94	p < 0.001	0.0%
Not mention	2	265	2.64	1.87-3.73	p < 0.001	46.2%
Sample size
n < 200	5	724	2.27	1.80-2.88	p < 0.001	0.0%
n > 200	2	422	2.78	1.94-3.97	p < 0.001	0.0%
GPS subtype
GPS	6	940	2.27	1.83-2.83	p < 0.001	0.0%
Hs-mGPS	1	206	3.16	2.00-5.00	p < 0.001	—
Metastasis status
With metastatic cases	6	984	2.27	1.83-2.81	p < 0.001	0.0%
Without metastatic cases	1	162	3.39	2.06-5.57	p < 0.001	—